PARP抑制剂-话题@MedSci

#PARP抑制剂#

13篇内容 | 3227人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1222005, encodeId=d968122200559, content=<a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>, objectTitle=PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS, objectType=article, longId=302295, objectId=5d50302295d1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202242/1648908301906_5295902.png, objectUrl=/article/show_article.do?id=5d50302295d1, replyNumber=0, likeNumber=135, createdTime=2022-05-24, rootId=0, userName=清风徐来2022, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d50302295d1, moduleTitle=PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d50302295d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1222004, encodeId=f7ff12220040c, content=<a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>, objectTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, objectType=article, longId=302280, objectId=14b430228084, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220326/84c17e4b503b4d68b1d6cd1efd1bc21c.jpg, objectUrl=/article/show_article.do?id=14b430228084, replyNumber=0, likeNumber=136, createdTime=2022-05-24, rootId=0, userName=清风徐来2022, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14b430228084, moduleTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14b430228084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1222003, encodeId=f5de1222003e8, content=<a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>, objectTitle=PARP抑制剂不良反应管理的中国专家共识, objectType=guider, longId=15333, objectId=8fcc01c002269af7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=8fcc01c002269af7, replyNumber=0, likeNumber=148, createdTime=2022-05-24, rootId=0, userName=清风徐来2022, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fcc01c002269af7, moduleTitle=PARP抑制剂不良反应管理的中国专家共识, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=8fcc01c002269af7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1222002, encodeId=cb7312220029a, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a><a href='/topic/show?id=d3c65861e2f' target=_blank style='color:#2F92EE;'>#新药#</a><a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>纳入<a href='/topic/show?id=e85c33804e5' target=_blank style='color:#2F92EE;'>#医保#</a>, objectTitle=卵巢癌新药纳入医保专家：患者月均自付费用低至两三千元, objectType=article, longId=208021, objectId=3d01208021e0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202137/1615048421614_2119349.jpg, objectUrl=/article/show_article.do?id=3d01208021e0, replyNumber=0, likeNumber=191, createdTime=2022-05-24, rootId=0, userName=清风徐来2022, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d01208021e0, moduleTitle=卵巢癌新药纳入医保专家：患者月均自付费用低至两三千元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d01208021e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=911522, encodeId=b58b911522a8, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a><a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>, objectTitle=Science Advances：PARP1抑制剂有望成为PDAC有效治疗策略, objectType=article, longId=204928, objectId=dd4e20492868, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20201224/abfb4c26bf824710b8692a67f192327e.png, objectUrl=/article/show_article.do?id=dd4e20492868, replyNumber=0, likeNumber=258, createdTime=2020-12-28, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd4e20492868, moduleTitle=Science Advances：PARP1抑制剂有望成为PDAC有效治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd4e20492868)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=809953, encodeId=41d180995302, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>，<a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>作用仍很小，仅仅微有提高而已。需要突破性药物问世, objectTitle=2020 SGO实践声明：卵巢癌前线PARP抑制剂维持治疗 , objectType=guider, longId=12180, objectId=ef9321c00195a15f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=ef9321c00195a15f, replyNumber=0, likeNumber=320, createdTime=2020-08-18, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef9321c00195a15f, moduleTitle=2020 SGO实践声明：卵巢癌前线PARP抑制剂维持治疗 , moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=ef9321c00195a15f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PARP抑制剂

2020-05-29

清风徐来2022 (审核中...)

前往app查看评论内容

#PARP抑制剂#

PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS

2022-05-24

清风徐来2022 (审核中...)

前往app查看评论内容

#PARP抑制剂#

Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究

2022-05-24

清风徐来2022 (审核中...)

前往app查看评论内容

#PARP抑制剂#

PARP抑制剂不良反应管理的中国专家共识

2022-05-24

清风徐来2022 (审核中...)

前往app查看评论内容

#卵巢癌##新药##PARP抑制剂#纳入#医保#

卵巢癌新药纳入医保专家：患者月均自付费用低至两三千元

2022-05-24

lovetcm (审核中...)

前往app查看评论内容

#胰腺癌##PARP抑制剂#

Science Advances：PARP1抑制剂有望成为PDAC有效治疗策略

2020-12-28

lovetcm (审核中...)

前往app查看评论内容

#卵巢癌#，#PARP抑制剂#作用仍很小，仅仅微有提高而已。需要突破性药物问世

2020 SGO实践声明：卵巢癌前线PARP抑制剂维持治疗

2020-08-18

科室
- - 订阅+
  - 更多科室
工具
服务